W W Grainger Inc vs 22nd Century Group Inc — how do they compare? W W Grainger Inc trades at $1,400.72 (market cap $64.75B), while 22nd Century Group Inc trades at $4.27 (market cap $1.52M). The key difference: W W Grainger Inc is far larger — about 42598.7× 22nd Century Group Inc's market cap, and W W Grainger Inc pays a 0.68% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| GWW | XXII | |
|---|---|---|
Market Cap | $64.75B | $1.52M |
Sector | Technology | Technology |
52-Week High | $1.39K | $1.47K |
52-Week Low | $918.18 | $3.90 |
Enterprise Value | $66.84B | -$6.71M |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,398.30, up 1.99% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q1 2026 earnings of $11.65 per share, beating estimates, and raised its full-year guidance. Revenue growth and profitability remain solid, with a net income margin of 9.7% and ROE of 48.1% for 2025. Recent news highlights its inclusion in high-quality dividend and momentum stock lists, reflecting positive market recognition.
The outlook for GWW is positive, driven by earnings beats and upward guidance revisions, though valuation multiples like a P/E of 36.88 suggest premium pricing. Risks include competitive pressures in the industrial services sector and reliance on MRO market demand. Analyst consensus is cautious with a hold-heavy rating, but the average price target of $1,260 implies modest upside potential from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →